Genomics of Hepatocellular Carcinoma

  • Chunming Wong
  • Irene Oi Lin Ng

Abstract

Hepatocarcinogenesis is a multistep process developing from a normal liver through chronic hepatitis and cirrhosis to HCC. The pathogenesis of HCC is poorly understood at present. There is insufficient understanding to propose a robust general model of hepatic carcinogenesis, partly because the pathogenic host and environmental factors show significant regional variation, making such generalization difficult. However, with advances in molecular technology, there is a growing understanding of the molecular mechanisms in the development of HCC. In hepatocarcinogenesis, there is a strong link to increases in allelic losses, chromosomal changes, gene mutations, epigenetic alterations and alterations in molecular cellular pathways. In this chapter, special focus is placed on the multistep process of hepatocarcinogenesis, genetics, epigenetics and regulation of major signaling pathways involved in hepatocarcinogenesis. A detailed understanding of the molecular pathogenesis involved in the progression of HCC can improve our prevention and diagnostic tools for HCC and may help identify novel molecular targets for new therapies.

Keywords

Hepatocellular Carcinoma Comparative Genomic Hybridization Adenomatous Polyposis Coli Human Hepatocellular Carcinoma Allelic Loss 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Roncalli M. Hepatocellular nodules in cirrhosis: focus on diagnostic criteria on liver biopsy. A Western experience. Liver Transpl, 2004, 10: S9–S15.Google Scholar
  2. [2]
    Ferrell L D, Crawford J M, Dhillon A P, et al. Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol, 1993, 17: 1113–1123.PubMedGoogle Scholar
  3. [3]
    Kobayashi M, Ikeda K, Hosaka T, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer, 2006, 106: 636–647.PubMedGoogle Scholar
  4. [4]
    Mion F, Grozel L, Boillot O, et al. Adult cirrhotic liver explants: precancerous lesions and undetected small hepatocellular carcinomas. Gastroenterology, 1996, 111: 1587–1592.PubMedGoogle Scholar
  5. [5]
    Lee J M, Wong C M, Ng I O. Hepatitis B virus-associated multistep hepatocarcinogenesis: a stepwise increase in allelic alterations. Cancer Res, 2008, 68: 5988–5996.PubMedGoogle Scholar
  6. [6]
    Thursz M R, Kwiatkowski D, Allsopp C E, et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med, 1995, 332: 1065–1069.PubMedGoogle Scholar
  7. [7]
    Hohler T, Gerken G, Notghi A, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol, 1997, 26: 503–507.PubMedGoogle Scholar
  8. [8]
    Ahn S H, Han K H, Park J Y, et al. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology, 2000, 31: 1371–1373.PubMedGoogle Scholar
  9. [9]
    Bellamy R, Ruwende C, Corrah T, et al. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis, 1999, 179: 721–724.PubMedGoogle Scholar
  10. [10]
    Deng G, Zhou G, Zhai Y, et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology, 2004, 40: 318–326.PubMedGoogle Scholar
  11. [11]
    King J K, Yeh S H, Lin M W, et al. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. Hepatology, 2002, 36: 1416–1424.PubMedGoogle Scholar
  12. [12]
    Yu M W, Chang H C, Liaw Y F, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst, 2000, 92: 1159–1164.PubMedGoogle Scholar
  13. [13]
    Yu M W, Chang H C, Chen P J, et al. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol, 2002, 31: 1008–1015.PubMedGoogle Scholar
  14. [14]
    Kummee P, Tangkijvanich P, Poovorawan Y, et al. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat, 2007, 14: 841–848.PubMedGoogle Scholar
  15. [15]
    Gu X, Qi P, Zhou F, et al. +49G>A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol, 2010, 71: 83–87.PubMedGoogle Scholar
  16. [16]
    Patil M A, Gutgemann I, Zhang J, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis, 2005, 26: 2050–2057.PubMedGoogle Scholar
  17. [17]
    Yoon Y J, Chang H Y, Ahn S H, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 2008, 29:1192–1196.PubMedGoogle Scholar
  18. [18]
    Migita K, Miyazoe S, Maeda Y, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection: association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol, 2005, 42: 505–510.PubMedGoogle Scholar
  19. [19]
    Tseng C S, Tang K S, Lo H W, et al. UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age. Am J Gastroenterol, 2005, 100: 1758–1763.PubMedGoogle Scholar
  20. [20]
    Shih W L, Yu M W, Chen P J, et al. Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. Oncogene, 2006, 25: 3219–3124.PubMedGoogle Scholar
  21. [21]
    Xu T, Zhu Y, Wei Q K, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis, 2008, 29: 2126–2131.PubMedGoogle Scholar
  22. [22]
    Nagasue N, Yamanoi A, Takemoto Y, et al. Comparison between diploid and aneuploid hepatocellular carcinomas: a flow cytometric study. Br J Surg, 1992, 79: 667–670.PubMedGoogle Scholar
  23. [23]
    Attallah A M, Tabll A A, Salem S F, et al. DNA ploidy of liver biopsies from patients with liver cirrhosis and hepatocellular carcinoma: a flow cytometric analysis. Cancer Lett, 1999, 142: 65–69.PubMedGoogle Scholar
  24. [24]
    Kawai H, Suda T, Aoyagi Y, et al. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology, 2000, 31: 1246–1250.PubMedGoogle Scholar
  25. [25]
    Kuroki T, Fujiwara Y, Tsuchiya E, et al. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer, 1995, 13: 163–167.PubMedGoogle Scholar
  26. [26]
    Li S P, Wang H Y, Li J Q, et al. Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. J Hepatol, 2001, 34: 840–849.PubMedGoogle Scholar
  27. [27]
    Nagai H, Pineau P, Tiollais P, et al. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene, 1997, 14: 2927–2933.PubMedGoogle Scholar
  28. [28]
    Okabe H, Ikai I, Matsuo K, et al. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and-negative tumors. Hepatology, 2000, 31: 1073–1079.PubMedGoogle Scholar
  29. [29]
    Piao Z, Park C, Park J H, et al. Allelotype analysis of hepatocellular carcinoma. Int J Cancer, 1998, 75: 29–33.PubMedGoogle Scholar
  30. [30]
    Bando K, Nagai H, Matsumoto S, et al. Identification of a 1-cM region of common deletion on 4q35 associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer, 1999, 25: 284–289.PubMedGoogle Scholar
  31. [31]
    Bluteau O, Beaudoin J C, Pasturaud P, et al. Specific association between alcohol intake, high grade of differentiation and 4q34–q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene, 2002, 21: 1225–1232.PubMedGoogle Scholar
  32. [32]
    Chan K L, Lee J M, Guan X Y, et al. High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. Cancer, 2002, 94: 3179–3185.PubMedGoogle Scholar
  33. [33]
    Emi M, Fujiwara Y, Ohata H, et al. Allelic loss at chromosome band 8p21.3–p22 is associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer, 1993, 7: 152–157.PubMedGoogle Scholar
  34. [34]
    Piao Z, Park C, Park J H, et al. Deletion mapping of chromosome 4q in hepatocellular carcinoma. Int J Cancer, 1998, 79: 356–360.PubMedGoogle Scholar
  35. [35]
    Pineau P, Nagai H, Prigent S, et al. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma. Oncogene, 1999, 18: 3127–3134.PubMedGoogle Scholar
  36. [36]
    Wong C M, Lee J M, Lau T C, et al. Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res, 2002, 8: 2266–2272.PubMedGoogle Scholar
  37. [37]
    Tamura S, Nakamori S, Kuroki T, et al. Association of cumulative allelic losses with tumor aggressiveness in hepatocellular carcinoma. J Hepatol, 1997, 27: 669–676.PubMedGoogle Scholar
  38. [38]
    Raidl M, Pirker C, Schulte-Hermann R, et al. Multiple chromosomal abnormalities in human liver (pre)neoplasia. J Hepatol, 2004, 40: 660–668.PubMedGoogle Scholar
  39. [39]
    Kahng Y S, Lee Y S, Kim B K, et al. Loss of heterozygosity of chromosome 8p and 11p in the dysplastic nodule and hepatocellular carcinoma. J Gastroenterol Hepatol, 2003, 18: 430–436.PubMedGoogle Scholar
  40. [40]
    Sun M, Eshleman J R, Ferrell L D, et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36–p34 region. Hepatology, 2001, 33: 1415–1424.PubMedGoogle Scholar
  41. [41]
    Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology, 2001, 120: 1763–1773.PubMedGoogle Scholar
  42. [42]
    Kallioniemi A, Kallioniemi O P, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science, 1992, 258: 818–821.PubMedGoogle Scholar
  43. [43]
    Marchio A, Meddeb M, Pineau P, et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer, 1997, 18: 59–65.PubMedGoogle Scholar
  44. [44]
    Zondervan P E, Wink J, Alers J C, et al. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol, 2000, 192: 207–215.PubMedGoogle Scholar
  45. [45]
    Wong N, Lai P, Lee S W, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol, 1999, 154: 37–43.PubMedGoogle Scholar
  46. [46]
    Tornillo L, Carafa V, Richter J, et al. Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas. J Pathol, 2000, 192: 307–312.PubMedGoogle Scholar
  47. [47]
    Kusano N, Shiraishi K, Kubo K, et al. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology, 1999, 29: 1858–1862.PubMedGoogle Scholar
  48. [48]
    Guan X Y, Fang Y, Sham J S, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer, 2000, 29: 110–116.PubMedGoogle Scholar
  49. [49]
    Collonge-Rame M A, Bresson-Hadni S, Koch S, et al. Pattern of chromosomal imbalances in non-B virus related hepatocellular carcinoma detected by comparative genomic hybridization. Cancer Genet Cytogenet, 2001, 127: 49–52.PubMedGoogle Scholar
  50. [50]
    Kusano N, Okita K, Shirahashi H, et al. Chromosomal imbalances detected by comparative genomic hybridization are associated with outcome of patients with hepatocellular carcinoma. Cancer, 2002, 94: 746–751.PubMedGoogle Scholar
  51. [51]
    Sakakura C, Hagiwara A, Taniguchi H, et al. Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization. Br J Cancer, 1999, 80: 2034–2039.PubMedGoogle Scholar
  52. [52]
    Fang W, Piao Z, Simon D, et al. Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13–p36.23 and mutational analysis of the RIZ (PRDM2) gene localized to the region. Genes Chromosomes Cancer, 2000, 28: 269–275.PubMedGoogle Scholar
  53. [53]
    Russell S E, McIlhatton M A, Burrows J F, et al. Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Res, 2000, 60: 4729–4734.PubMedGoogle Scholar
  54. [54]
    Albertson D G, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet, 2000, 25: 144–146.PubMedGoogle Scholar
  55. [55]
    Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet, 1998, 20: 207–211.PubMedGoogle Scholar
  56. [56]
    Ching Y P, Wong C M, Chan S F, et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem, 2003, 278: 10824–10830.PubMedGoogle Scholar
  57. [57]
    Wong C C, Wong C M, Ko F C, et al. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One, 2008, 3: e2779.PubMedGoogle Scholar
  58. [58]
    Leung T H, Ching Y P, Yam J W, et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA, 2005, 102: 15207–15212.PubMedGoogle Scholar
  59. [59]
    Wong C M, Yam J W, Ching Y P, et al. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res, 2005, 65: 8861–8868.PubMedGoogle Scholar
  60. [60]
    Zhou X, Thorgeirsson S S, Popescu N C. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene, 2004, 23: 1308–1313.PubMedGoogle Scholar
  61. [61]
    Cheng I K, Ching A K, Chan T C, et al. Reduced CRYL1 expression in hepatocellular carcinoma confers cell growth advantages and correlates with adverse patient prognosis. J Pathol, 2009, 220: 348–360.Google Scholar
  62. [62]
    Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature, 1999, 398: 160–165.PubMedGoogle Scholar
  63. [63]
    Ruddon R W (ed). Cancer Biology. 3rd edn. New York: Oxford University Press, 1995.Google Scholar
  64. [64]
    Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet, 1991, 338: 1356–1359.PubMedGoogle Scholar
  65. [65]
    Scorsone K A, Zhou Y Z, Butel J S, et al. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res, 1992, 52: 1635–1638.PubMedGoogle Scholar
  66. [66]
    Ng I O, Chung L P, Tsang S W, et al. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene, 1994, 9: 985–990.PubMedGoogle Scholar
  67. [67]
    Ng I O, Lai E C, Chan A S, et al. Overexpression of p53 in hepatocellular carcinomas: a clinicopathological and prognostic correlation. J Gastroenterol Hepatol, 1995, 10: 250–255.PubMedGoogle Scholar
  68. [68]
    Hsu I C, Metcalf R A, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 1991, 350: 427–428.PubMedGoogle Scholar
  69. [69]
    Dumenco L, Oguey D, Wu J, et al. Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. Hepatology, 1995, 22: 1279–1288.PubMedGoogle Scholar
  70. [70]
    Ponchel F, Puisieux A, Tabone E, et al. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res, 1994, 54: 2064–2068.PubMedGoogle Scholar
  71. [71]
    Eferl R, Ricci R, Kenner L, et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell, 2003, 112: 181–192.PubMedGoogle Scholar
  72. [72]
    Wong C M, Fan S T, Ng I O. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer, 2001, 92: 136–145.PubMedGoogle Scholar
  73. [73]
    Terris B, Pineau P, Bregeaud L, et al. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene, 1999, 18: 6583–6588.PubMedGoogle Scholar
  74. [74]
    de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA, 1998, 95: 8847–8851.Google Scholar
  75. [75]
    Hsu H C, Jeng Y M, Mao T L, et al. beta-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol, 2000, 157: 763–770.PubMedGoogle Scholar
  76. [76]
    Taniguchi K, Roberts L R, Aderca I N, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene, 2002, 21: 4863–4871.PubMedGoogle Scholar
  77. [77]
    Nhieu J T, Renard C A, Wei Y, et al. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol, 1999, 155: 703–710.PubMedGoogle Scholar
  78. [78]
    Cieply B, Zeng G, Proverbs-Singh T, et al. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology, 2009, 49: 821–831.PubMedGoogle Scholar
  79. [79]
    Nishida N, Nishimura T, Nagasaka T, et al. Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res, 2007, 67: 4586–4594.PubMedGoogle Scholar
  80. [80]
    Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet, 2003, 33 Suppl: 228–237.PubMedGoogle Scholar
  81. [81]
    Risch N J. Searching for genetic determinants in the new millennium. Nature, 2000, 405: 847–856.PubMedGoogle Scholar
  82. [82]
    Shin H D, Park B L, Kim L H, et al. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet, 2003, 12: 901–906.PubMedGoogle Scholar
  83. [83]
    Miyazoe S, Hamasaki K, Nakata K, et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol, 2002, 97: 2086–2092.PubMedGoogle Scholar
  84. [84]
    Zhai Y, Zhou G, Deng G, et al. Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology, 2006, 130: 2001–2009.PubMedGoogle Scholar
  85. [85]
    Saffroy R, Pham P, Chiappini F, et al. The MTHFR 677C>T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis, 2004, 25: 1443–1448.PubMedGoogle Scholar
  86. [86]
    Yuan J M, Lu S C, Van Den Berg D, et al. Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma. Hepatology, 2007, 46: 749–758.PubMedGoogle Scholar
  87. [87]
    Wang X Q, Luk J M, Garcia-Barcelo M, et al. Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinoma. Clin Cancer Res, 2006, 12: 5248–5252.PubMedGoogle Scholar
  88. [88]
    Segat L, Milanese M, Pirulli D, et al. Secreted protein acidic and rich in cysteine (SPARC) gene polymorphism association with hepatocellular carcinoma in Italian patients. J Gastroenterol Hepatol, 2009, 24: 1840–1846.PubMedGoogle Scholar
  89. [89]
    Kim Y S, Cheong J Y, Cho S W, et al. A functional snp of the interleukin-18 gene is associated with the presence of hepatocellular carcinoma in hepatitis B virus-infected patients. Dig Dis Sci, 2009, 54: 2722–2728.PubMedGoogle Scholar
  90. [90]
    Ezzikouri S, El Feydi A E, Benazzouz M, et al. Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol, 2009, 9: 877–881.PubMedGoogle Scholar
  91. [91]
    Wu Y, Lin J S. DNA methyltransferase 3B promoter polymorphism and its susceptibility to primary hepatocellular carcinoma in the Chinese Han nationality population: a case-control study. World J Gastroenterol, 2007, 13: 6082–6086.PubMedGoogle Scholar
  92. [92]
    Hunter D J, Kraft P, Jacobs K B, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet, 2007, 39: 870–874.PubMedGoogle Scholar
  93. [93]
    Easton D F, Pooley K A, Dunning A M, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447: 1087–1093.PubMedGoogle Scholar
  94. [94]
    Li E, Bestor T H, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell, 1992, 69: 915–926.PubMedGoogle Scholar
  95. [95]
    Wong N, Lam W C, Lai P B, et al. Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma. Am J Pathol, 2001, 159: 465–471.PubMedGoogle Scholar
  96. [96]
    Saito Y, Kanai Y, Sakamoto M, et al. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology, 2001, 33: 561–568.PubMedGoogle Scholar
  97. [97]
    Nambu S, Inoue K, Saski H. Site-specific hypomethylation of the c-myc oncogene in human hepatocellular carcinoma. Jpn J Cancer Res, 1987, 78: 695–704.PubMedGoogle Scholar
  98. [98]
    Lin C H, Hsieh S Y, Sheen I S, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res, 2001, 61: 4238–4243.PubMedGoogle Scholar
  99. [99]
    Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA, 1993, 90: 11995–11999.PubMedGoogle Scholar
  100. [100]
    Panning B, Jaenisch R. RNA and the epigenetic regulation of X chromosome inactivation. Cell, 1998, 93: 305–308.PubMedGoogle Scholar
  101. [101]
    Greger V, Passarge E, Hopping W, et al. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet, 1989, 83: 155–158.PubMedGoogle Scholar
  102. [102]
    Kanai Y, Ushijima S, Hui A M, et al. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer, 1997, 71: 355–359.PubMedGoogle Scholar
  103. [103]
    Kaneto H, Sasaki S, Yamamoto H, et al. Detection of hypermethylation of the p16 (INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut, 2001, 48: 372–377.PubMedGoogle Scholar
  104. [104]
    Oh B K, Kim H, Park H J, et al. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med, 2007, 20: 65–73.PubMedGoogle Scholar
  105. [105]
    Lee S, Lee H J, Kim J H, et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol, 2003, 163: 1371–1378.PubMedGoogle Scholar
  106. [106]
    Schagdarsurengin U, Wilkens L, Steinemann D, et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene, 2003, 22: 1866–1871.PubMedGoogle Scholar
  107. [107]
    Zhong S, Tang M W, Yeo W, et al. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res, 2002, 8: 1087–1092.PubMedGoogle Scholar
  108. [108]
    Yoshikawa H, Matsubara K, Qian G S, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet, 2001, 28: 29–35.PubMedGoogle Scholar
  109. [109]
    Shih Y L, Shyu R Y, Hsieh C B, et al. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer, 2006, 107: 579–590.PubMedGoogle Scholar
  110. [110]
    Wong C M, Lee J M, Ching Y P, et al. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res, 2003, 63: 7646–7651.PubMedGoogle Scholar
  111. [111]
    Wang L, Wang W L, Zhang Y, et al. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res, 2007, 37: 389–396.PubMedGoogle Scholar
  112. [112]
    Wong I H, Lo Y M, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res, 1999, 59: 71–73.PubMedGoogle Scholar
  113. [113]
    Zhang Y J, Wu H C, Shen J, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res, 2007, 13: 2378–2384.PubMedGoogle Scholar
  114. [114]
    Lee R C, Feinbaum R L, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75: 843–854.PubMedGoogle Scholar
  115. [115]
    Alvarez-Garcia I, Miska E A. MicroRNA functions in animal development and human disease. Development, 2005, 132: 4653–4662.PubMedGoogle Scholar
  116. [116]
    Slack F J, Basson M, Liu Z, et al. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. Mol Cell, 2000, 5: 659–669.PubMedGoogle Scholar
  117. [117]
    Calin G A, Dumitru C D, Shimizu M, et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA, 2002, 99: 15524–15529.PubMedGoogle Scholar
  118. [118]
    Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res, 2007, 67: 6092–6099.PubMedGoogle Scholar
  119. [119]
    Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007, 133: 647–658.PubMedGoogle Scholar
  120. [120]
    Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of micro RNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 2006, 25: 2537–2545.PubMedGoogle Scholar
  121. [121]
    Budhu A, Jia H L, Forgues M, et al. Identification of metastasis-related micro RNAs in hepatocellular carcinoma. Hepatology, 2008, 47: 897–907.PubMedGoogle Scholar
  122. [122]
    Jiang J, Gusev Y, Aderca I, et al. Association of micro RNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res, 2008, 14: 419–427.PubMedGoogle Scholar
  123. [123]
    Wang Y, Kato N, Jazag A, et al. Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology, 2006, 130: 883–892.PubMedGoogle Scholar
  124. [124]
    Melo S A, Ropero S, Moutinho C, et al. A TARBP2 mutation in human cancer impairs micro RNA processing and DICER1 function. Nat Genet, 2009, 41: 365–370.PubMedGoogle Scholar
  125. [125]
    He L, Thomson J M, Hemann M T, et al. A micro RNA polycistron as a potential human oncogene. Nature, 2005, 435: 828–833.PubMedGoogle Scholar
  126. [126]
    Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008, 27: 5651–5661.PubMedGoogle Scholar
  127. [127]
    Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA, 2010, 107: 264–269.PubMedGoogle Scholar
  128. [128]
    Coulouarn C, Factor V M, Andersen J B, et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene, 2009, 28: 3526–3536.PubMedGoogle Scholar
  129. [129]
    Lin C J, Gong H Y, Tseng H C, et al. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun, 2008, 375: 315–320.PubMedGoogle Scholar
  130. [130]
    Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 2009, 361: 1437–1447.PubMedGoogle Scholar
  131. [131]
    Kota J, Chivukula R R, O’Donnell K A, et al. Therapeutic micro RNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009, 137: 1005–1017.PubMedGoogle Scholar
  132. [132]
    Chen X, Cheung S T, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell, 2002, 13: 1929–1939.PubMedGoogle Scholar
  133. [133]
    Delpuech O, Trabut J B, Carnot F, et al. Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. Oncogene, 2002, 21: 2926–2937.PubMedGoogle Scholar
  134. [134]
    Goldenberg D, Ayesh S, Schneider T, et al. Analysis of differentially expressed genes in hepatocellular carcinoma using cDNA arrays. Mol Carcinog, 2002, 33: 113–124.PubMedGoogle Scholar
  135. [135]
    Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res, 2001, 61: 2129–2137.PubMedGoogle Scholar
  136. [136]
    Shirota Y, Kaneko S, Honda M, et al. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology, 2001, 33: 832–840.PubMedGoogle Scholar
  137. [137]
    Xu L, Hui L, Wang S, et al. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res, 2001, 61: 3176–3181.PubMedGoogle Scholar
  138. [138]
    Xu X R, Huang J, Xu Z G, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA, 2001, 98: 15089–15094.PubMedGoogle Scholar
  139. [139]
    Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis B virus-and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res, 2002, 62: 3939–3944.PubMedGoogle Scholar
  140. [140]
    Westermarck J, Kahari V M. Regulation of matrix metalloproteinase expression in tumor invasion. Faseb J, 1999, 13: 781–792.PubMedGoogle Scholar
  141. [141]
    Maatta M, Soini Y, Liakka A, et al. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res, 2000, 6: 2726–2734.PubMedGoogle Scholar
  142. [142]
    Clark E A, Golub T R, Lander E S, et al. Genomic analysis of metastasis reveals an essential role for RhoC. Nature, 2000, 406: 532–535.PubMedGoogle Scholar
  143. [143]
    Hakem A, Sanchez-Sweatman O, You-Ten A, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev, 2005, 19: 1974–1979.PubMedGoogle Scholar
  144. [144]
    Wang W, Yang L Y, Huang G W, et al. Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer, 2004, 90: 2349–2355.PubMedGoogle Scholar
  145. [145]
    Wang W, Yang L Y, Yang Z L, et al. Expression and significance of RhoC gene in hepatocellular carcinoma. World J Gastroenterol, 2003, 9: 1950–1953.PubMedGoogle Scholar
  146. [146]
    Huang J, Sheng H H, Shen T, et al. Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma. FEBS Lett, 2006, 580: 3571–3581.PubMedGoogle Scholar
  147. [147]
    Lee S A, Ho C, Roy R, et al. Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology, 2008, 47: 1200–1210.PubMedGoogle Scholar
  148. [148]
    El-Serag H B, Rudolph K L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132: 2557–2576.PubMedGoogle Scholar
  149. [149]
    Villanueva A, Newell P, Chiang D Y, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis, 2007, 27: 55–76.PubMedGoogle Scholar
  150. [150]
    Huelsken J, Behrens J. The Wnt signalling pathway. J Cell Sci, 2002, 115: 3977–3978.PubMedGoogle Scholar
  151. [151]
    Clevers H. Wnt/beta-catenin signaling in development and disease. Cell, 2006, 127: 469–480.PubMedGoogle Scholar
  152. [152]
    Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol, 2007, 19: 150–158.PubMedGoogle Scholar
  153. [153]
    He T C, Sparks A B, Rago C, et al. Identification of c-myc as a target of the APC pathway. Science, 1998, 281: 1509–1512.PubMedGoogle Scholar
  154. [154]
    Tetsu O, McCormick F. beta-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature, 1999, 398: 422–426.PubMedGoogle Scholar
  155. [155]
    Huang H, Fujii H, Sankila A, et al. beta-Catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol, 1999, 155: 1795–1801.PubMedGoogle Scholar
  156. [156]
    Cui J, Zhou X, Liu Y, et al. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. J Gastroenterol Hepatol, 2003, 18: 280–287.PubMedGoogle Scholar
  157. [157]
    Cottrell S, Bicknell D, Kaklamanis L, et al. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet, 1992, 340: 626–630.PubMedGoogle Scholar
  158. [158]
    Yang B, Guo M, Herman J G, et al. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol, 2003, 163: 1101–1107.PubMedGoogle Scholar
  159. [159]
    Colnot S, Decaens T, Niwa-Kawakita M, et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA, 2004, 101: 17216–17221.PubMedGoogle Scholar
  160. [160]
    Ryo A, Nakamura M, Wulf G, et al. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol, 2001, 3: 793–801.PubMedGoogle Scholar
  161. [161]
    Pang R, Yuen J, Yuen M F, et al. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene, 2004, 23: 4182–4186.PubMedGoogle Scholar
  162. [162]
    Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet, 2000, 24: 245–250.PubMedGoogle Scholar
  163. [163]
    Chan D W, Chan C Y, Yam J W, et al. Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/ degradation in liver cancer. Gastroenterology, 2006, 131: 1218–1227.PubMedGoogle Scholar
  164. [164]
    Uematsu K, He B, You L, et al. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene, 2003, 22: 7218–7221.PubMedGoogle Scholar
  165. [165]
    Uematsu K, Kanazawa S, You L, et al. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res, 2003, 63: 4547–4551.PubMedGoogle Scholar
  166. [166]
    Yau T O, Chan C Y, Chan K L, et al. HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. Oncogene, 2005, 24: 1607–1614.PubMedGoogle Scholar
  167. [167]
    Bengochea A, de Souza M M, Lefrancois L, et al. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer, 2008, 99: 143–150.PubMedGoogle Scholar
  168. [168]
    Kim M, Lee H C, Tsedensodnom O, et al. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol, 2008, 48: 780–791.PubMedGoogle Scholar
  169. [169]
    Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci, 2003, 116: 2627–2634.PubMedGoogle Scholar
  170. [170]
    Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet, 2002, 31: 141–149.PubMedGoogle Scholar
  171. [171]
    Takagi H, Sasaki S, Suzuki H, et al. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol, 2008, 43: 378–389.PubMedGoogle Scholar
  172. [172]
    Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature, 2001, 411: 321–325.PubMedGoogle Scholar
  173. [173]
    Qin X, Zhang H, Zhou X, et al. Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells. Transl Res, 2007, 150: 281–294.PubMedGoogle Scholar
  174. [174]
    Merle P, de la Monte S, Kim M, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology, 2004, 127: 1110–1122.PubMedGoogle Scholar
  175. [175]
    Merle P, Kim M, Herrmann M, et al. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol, 2005, 43: 854–862.PubMedGoogle Scholar
  176. [176]
    Tolwinski N S, Wehrli M, Rives A, et al. Wg/Wnt signal can be transmitted through arrow/LRP5,6 and Axin independently of Zw3/Gsk3beta activity. Dev Cell, 2003, 4: 407–418.PubMedGoogle Scholar
  177. [177]
    Tamai K, Semenov M, Kato Y, et al. LDL-receptor-related proteins in Wnt signal transduction. Nature, 2000, 407: 530–535.PubMedGoogle Scholar
  178. [178]
    Satoh T, Kaziro Y. Ras in signal transduction. Semin Cancer Biol, 1992, 3: 169–177.PubMedGoogle Scholar
  179. [179]
    Vojtek A B, Der C J. Increasing complexity of the Ras signaling pathway. J Biol Chem, 1998, 273: 19925–19928.PubMedGoogle Scholar
  180. [180]
    Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev, 1998, 8: 49–54.PubMedGoogle Scholar
  181. [181]
    Avruch J, Zhang X F, Kyriakis J M. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci, 1994, 19: 279–283.PubMedGoogle Scholar
  182. [182]
    Ogata N, Kamimura T, Asakura H. Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology, 1991, 13: 31–37.PubMedGoogle Scholar
  183. [183]
    Weihrauch M, Benicke M, Lehnert G, et al. Frequent k-ras-2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer, 2001, 84: 982–989.PubMedGoogle Scholar
  184. [184]
    Nonomura A, Ohta G, Hayashi M, et al. Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol, 1987, 82: 512–518.PubMedGoogle Scholar
  185. [185]
    Wang Q, Lin Z Y, Feng X L. Alterations in metastatic properties of hepatocellular carcinoma cell following H-ras oncogene transfection. World J Gastroenterol, 2001, 7: 335–339.PubMedGoogle Scholar
  186. [186]
    Jacob J R, Tennant B C. Transformation of immortalized woodchuck hepatic cell lines with the c-Ha-ras proto-oncogene. Carcinogenesis, 1996, 17: 631–636.PubMedGoogle Scholar
  187. [187]
    Osada S, Kanematsu M, Imai H, et al. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg, 2005, 201: 405–411.PubMedGoogle Scholar
  188. [188]
    Schuierer M M, Bataille F, Weiss T S, et al. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep, 2006, 16: 451–456.PubMedGoogle Scholar
  189. [189]
    Lee H C, Tian B, Sedivy J M, et al. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology, 2006, 131: 1208–1217.PubMedGoogle Scholar
  190. [190]
    Yoshida T, Hisamoto T, Akiba J, et al. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene, 2006, 25: 6056–6066.PubMedGoogle Scholar
  191. [191]
    Vos M D, Ellis C A, Bell A, et al. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem, 2000, 275: 35669–35672.PubMedGoogle Scholar
  192. [192]
    Calvisi D F, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and JAK/STAT pathways in human HCC. Gastroenterology, 2006, 130: 1117–1128.PubMedGoogle Scholar
  193. [193]
    Zhong S, Yeo W, Tang M W, et al. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin Cancer Res, 2003, 9: 3376–3382.PubMedGoogle Scholar
  194. [194]
    Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004, 304: 554.PubMedGoogle Scholar
  195. [195]
    Tanaka Y, Kanai F, Tada M, et al. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene, 2006, 25: 2950–2952.PubMedGoogle Scholar
  196. [196]
    Lee J W, Soung Y H, Kim S Y, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene, 2005, 24: 1477–1480.PubMedGoogle Scholar
  197. [197]
    Hu T H, Huang C C, Lin P R, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer, 2003, 97: 1929–1940.PubMedGoogle Scholar
  198. [198]
    Fujiwara Y, Hoon D S, Yamada T, et al. PTEN/MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas. Jpn J Cancer Res, 2000, 91: 287–292.PubMedGoogle Scholar
  199. [199]
    Bhaskar P T, Hay N. The two TORCs and Akt. Dev Cell, 2007, 12: 487–502.PubMedGoogle Scholar
  200. [200]
    Blanco-Aparicio C, Renner O, Leal J F, et al. PTEN, more than the Akt pathway. Carcinogenesis, 2007, 28: 1379–1386.PubMedGoogle Scholar
  201. [201]
    Nakanishi K, Sakamoto M, Yamasaki S, et al. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer, 2005, 103: 307–312.PubMedGoogle Scholar
  202. [202]
    Xu X, Sakon M, Nagano H, et al. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep, 2004, 11: 25–32.PubMedGoogle Scholar
  203. [203]
    Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 2005, 8: 179–183.PubMedGoogle Scholar
  204. [204]
    Sahin F, Kannangai R, Adegbola O, et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res, 2004, 10: 8421–8425.PubMedGoogle Scholar
  205. [205]
    Semela D, Piguet A C, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol, 2007, 46: 840–848.PubMedGoogle Scholar
  206. [206]
    Yuan B Z, Miller M J, Keck C L, et al. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res, 1998, 58: 2196–2199.PubMedGoogle Scholar
  207. [207]
    Ng I O, Liang Z D, Cao L, et al. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res, 2000, 60: 6581–6584.PubMedGoogle Scholar
  208. [208]
    Yam J W, Ko F C, Chan C Y, et al. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res, 2006, 66: 8367–8372.PubMedGoogle Scholar
  209. [209]
    Kim T Y, Lee J W, Kim H P, et al. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun, 2007, 355: 72–77.PubMedGoogle Scholar
  210. [210]
    Zhou X, Zimonjic D B, Park S W, et al. DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. Int J Oncol, 2008, 32: 1285–1291.PubMedGoogle Scholar
  211. [211]
    Xue W, Krasnitz A, Lucito R, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev, 2008, 22: 1439–1444.PubMedGoogle Scholar
  212. [212]
    Liao YC, Si L, deVere White RW, et al. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol, 2007, 176: 43–49.PubMedGoogle Scholar
  213. [213]
    Qian X, Li G, Asmussen H K, et al. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA, 2007, 104: 9012–9017.PubMedGoogle Scholar
  214. [214]
    Liao Y C, Shih Y P, Lo S H. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Res, 2008, 68: 7718–7722.PubMedGoogle Scholar
  215. [215]
    Zheng S L, Mychaleckyj J C, Hawkins G A, et al. Evaluation of DLC1 as a prostate cancer susceptibility gene: mutation screen and association study. Mutat Res, 2003, 528: 45–53.PubMedGoogle Scholar
  216. [216]
    Durkin M E, Ullmannova V, Guan M, et al. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene, 2007, 26: 4580–4589.PubMedGoogle Scholar
  217. [217]
    Kawai K, Kiyota M, Seike J, et al. START-GAP3/DLC3 is a GAP for RhoA and Cdc42 and is localized in focal adhesions regulating cell morphology. Biochem Biophys Res Commun, 2007, 364: 783–789.PubMedGoogle Scholar
  218. [218]
    Yam J W, Ko F C, Chan C Y, et al. Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. Hepatology, 2006, 44: 881–890.PubMedGoogle Scholar
  219. [219]
    Lin K H, Shieh H Y, Chen S L, et al. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog, 1999, 26: 53–61.PubMedGoogle Scholar
  220. [220]
    Yeh S H, Chiu C M, Chen C L, et al. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. Int J Cancer, 2007, 120: 1610–1617.PubMedGoogle Scholar
  221. [221]
    Soung Y H, Lee J W, Kim S Y, et al. Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. Oncogene, 2005, 24: 141–147.PubMedGoogle Scholar
  222. [222]
    Kremer-Tal S, Reeves H L, Narla G, et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology, 2004, 40: 1047–1052.PubMedGoogle Scholar
  223. [223]
    Cho Y G, Kim C J, Song J H, et al. Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas. Exp Mol Med, 2006, 38: 247–255.PubMedGoogle Scholar
  224. [224]
    Kim C J, Cho Y G, Park J Y, et al. Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. Eur J Cancer, 2004, 40: 136–141.PubMedGoogle Scholar
  225. [225]
    Xie H J, Bae H J, Noh J H, et al. Mutational analysis of JAK1 gene in human hepatocellular carcinoma. Neoplasma, 2009, 56: 136–140.PubMedGoogle Scholar

Copyright information

© Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Chunming Wong
    • 1
    • 2
  • Irene Oi Lin Ng
    • 1
    • 2
  1. 1.State Key Laboratory for Liver Research and Department of PathologyThe University of Hong KongHong Kong
  2. 2.Department of PathologyUniversity Pathology Building Queen Mary HospitalPokfulamHong Kong

Personalised recommendations